The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid

European Journal of Dermatology

Volumn 22, Issue 3, 2012, Pages 333-336

  Wakatabi, Koji ^a   Komine, Mayumi ^a   Meephansan, Jitlada ^a   Matsuyama, Yasushi ^a   Tsuda, Hidetoshi ^a   Tominaga, Shin Ichi ^a   Ohtsuki, Mamitaro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Bullous fluid; Bullous pemphigoid; IL 33; Serum; Soluble ST2

Indexed keywords

ANTIHISTAMINIC AGENT; BETAMETHASONE; BIOLOGICAL MARKER; INTERLEUKIN 33; LACTATE DEHYDROGENASE; NICOTINAMIDE; PREDNISOLONE; SOLUBLE ST2 PROTEIN; STEROID; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLISTER; BLOOD ANALYSIS; BODY FLUID; BULLOUS PEMPHIGOID; BURN PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN SURFACE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; L-LACTATE DEHYDROGENASE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; RECEPTORS, CELL SURFACE;

EID: 84863206072     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1706     Document Type: Article

References (21)

1. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pem-phigoid. Clin Rev Allergy Immunol 2007; 33: 67-77.
2. Kakinuma T, Wakugawa M, Nakamura K, Hino H, Matsushima K, Tamaki K. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br J Dermatol 2003; 148:203-210.
3. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008; 7:827-840.
4. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989; 258: 301-304.
5. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002; 32: 1520-1526.
6. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
7. Arend WP, Palmer G, Gabay C. IL-1. IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38.
8. Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181: 4780-4790.
9. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks IL-33 signalling in allergic airway inflammation. J Biol Chem 2007; 282:26369-26380.
10. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277-281.
11. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003; 124: 1206-1214.
12. Bhardwaj A, Januzzi JL Jr. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 2010; 10:459-464.
13. Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004; 30: 1468-1473.
14. Takezako N, Hayakawa M, Hayakawa H, Aoki S, Yanagisawa K, et al. ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. Biochem Biophys Res Commun 2006;341:425-432.
15. Matsuyama Y, Okazaki H, Tamemoto H, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010; 37: 18-25.
16. Tsukahara T, Otoyama K, Horiuchi Y. Significance of elevated serum squamous cell carcinoma (SCC)-related antigen and lactate dehydrogenase (LDH) levels in senile erythroderma following eczema. J Dermatol 1993; 20: 346-350.
17. Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology 2008; 217: 254-259.
18. Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol 1990; 17: 477-481.
19. Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001; 166: 6633-6639.
20. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 2010; 107:18581-18586.
21. Wakugawa M, Nakamura K, Hino H, et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol 2000; 143: 112-116.